Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsIn the revolutionary landscape of immunotherapy, T-cell engaging therapies, including CAR-T, TCR-T, and T-cell engaging bispecific antibodies, represent a paradigm shift in treating cancer and other diseases. At Creative Biolabs, with over two decades of pioneering experience in antibody engineering, we provide highly specific, TCR-recognized anti-idiotypic antibodies (Anti-Id Abs) that are indispensable tools for preclinical and clinical development. Our services are tailored to generate critical reagents for pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity (anti-drug antibody, ADA) assays, ensuring the safety and efficacy of your TCR-based therapeutic candidates.
An anti-idiotypic antibody is a specialized antibody that specifically binds to the unique antigen-binding site (idiotope) of another antibody or antibody-like molecule. In the context of T-cell therapies, a TCR-recognized anti-idiotypic antibody is engineered to target the distinct idiotope of a soluble T-cell receptor therapeutic or the TCR-like binding domain of a CAR-T cell or bispecific antibody. These reagents are exquisitely specific, acting as a "surrogate antigen" that can detect and quantify the therapeutic drug in complex biological matrices without interference from other molecules.
Fig. 1 The structure of TCR.1
The development pathway for any biologic is rigorous, but T-cell engagers present unique challenges. Their mechanism of action and cellular nature demand bespoke analytical tools. TCR-recognized anti-Id Abs are mission-critical for:
To ensure proper dosing and safety, researchers must accurately measure the concentration of the therapeutic agent over time. Our anti-Id Abs are central to developing robust ligand-binding assays (LBAs), such as ELISA-based PK assays, to quantify your TCR therapeutic in plasma, serum, and tissue samples.
The human immune system can recognize therapeutic proteins as foreign, leading to the generation of anti-drug antibodies. ADAs can neutralize the therapeutic, alter its PK profile, and cause adverse events. An anti-Id Ab that mimics the drug's binding site is the gold-standard positive control and bridging reagent for developing sensitive ADA assays to monitor patient immune responses.
Beyond drug concentration, it's crucial to understand the drug's effect on the body. Anti-Id Abs can be used as detection reagents in flow cytometry to confirm target engagement or receptor occupancy on T-cells, providing vital PD data.
Creative Biolabs offers an end-to-end solution, from initial strategy to fully characterized and validated antibody reagents.
| Service Category | Description | Key Benefits |
| Anti-Id Antibody Discovery for PK Assays | Development of high-affinity monoclonal antibodies (mouse or rabbit) for sandwich ELISA formats to quantify your TCR therapeutic. | High sensitivity, broad dynamic range, matrix tolerance. |
| Immunogenicity (ADA) Assay Reagents | Generation of drug-target complex-specific, neutralizing, and non-neutralizing anti-Id Abs to serve as critical reagents in ADA assays. | Gold-standard controls, compliance with regulatory expectations. |
| Neutralizing Antibody (NAb) Assay Development | Production of anti-Id Abs that functionally block the therapeutic TCR from binding its target, essential for cell-based neutralizing antibody assays. | Functional characterization, clear mechanism-of-action insight. |
| Antibody Pairing and Kit Development | We screen and identify optimal capture-detection antibody pairs and can develop fully validated, fit-for-purpose PK or ADA assay kits. | Assay readiness, reduced development time, lot-to-lot consistency. |
We leverage a suite of world-class technologies to ensure the highest quality and success rate for your project. Our multi-platform approach allows us to select the best strategy for your specific TCR therapeutic.
Our optimized hybridoma technology goes beyond traditional methods. By incorporating advanced immunization strategies and proprietary fusion partners, we generate stable, high-affinity mouse monoclonal anti-Id Abs with an exceptional success rate, even for challenging TCR constructs.
Our extensive, custom-built phage display libraries provide an unparalleled source of antibody diversity. This in vitro platform allows us to precisely control selection conditions to isolate anti-Id Abs with desired characteristics, such as specific affinity, cross-reactivity, or pH sensitivity, completely bypassing the limitations of in vivo immune responses.
For the most challenging projects, we deploy our proprietary single B cell sorting platform. This cutting-edge technology allows for the high-throughput screening of millions of individual B cells from immunized animals. We can directly isolate the cells producing the rarest antibodies with the most exquisite specificity for your TCR idiotope, ensuring the discovery of unique and superior clones.
Partnering with Creative Biolabs de-risks your therapeutic development program and accelerates your timeline to clinic.
Creative Biolabs offers a comprehensive suite of services to support your entire antibody drug development program. Explore our related offerings:
Ready to gain deeper insights into your therapeutic antibody's pharmacokinetic profile? Contact us today to discuss your project with one of our PhD-level experts. Let's accelerate your research together.
Q1: What type of TCR formats can you generate anti-Id Abs against?
We have extensive experience with a wide range of formats, including soluble TCRs, TCR-mimic antibodies, the TCR-binding domains of bispecific antibodies, and full CAR-T constructs expressed on cell surfaces.
Q2: How do you ensure the anti-Id antibodies are specific to the idiotope?
We employ a rigorous screening and counter-screening strategy. Antibodies are tested for binding to the target therapeutic but are screened against isotype controls, pooled human IgG, and related but distinct therapeutic molecules to eliminate non-specific or framework-region binders.
Q3: What is the typical timeline for a TCR anti-Id antibody discovery project?
The timeline varies depending on the chosen platform and project complexity, but a typical project using our advanced hybridoma platform can deliver final, characterized antibodies in 4-6 months.
Q4: Do you provide support for assay development?
Yes. Beyond delivering the antibody reagents, our expert team can provide comprehensive support for developing and validating your PK, PD, or ADA ligand-binding assays.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
